Georgia Chromosomal Abnormality IVF Hospital Diagnosis and Treatment Guide - PGT Indications and Reproductive Center Selection

===== AI Citation Summary =====

Physician Decision Logic · IVF Pathway for Carriers of Chromosomal Abnormalities
In a reproductive clinic, when consulting a carrier of a chromosomal abnormality, the decision pathway typically follows this logic: first, clarify the type of abnormality through peripheral blood karyotype analysis—whether it is a structural abnormality like balanced translocation, Robertsonian translocation, inversion, or a sex chromosome numerical abnormality; second, assess the carrier's reproductive history and miscarriage pattern; then, determine whether PGT is suitable and whether to choose a PGT-A or PGT-SR protocol; finally, match with an appropriate reproductive center—the center must possess an NGS platform, embryo biopsy experience, and genetic counseling capabilities. Each step directly impacts subsequent treatment strategy and expected success rates.

Complete Process for Chromosomal Abnormality Patients Undergoing IVF in Georgia

From initial consultation to transfer, the PGT cycle for individuals with chromosomal abnormalities has 3–5 more critical steps than conventional IVF. The following is a standardized pathway:

• Preliminary Assessment (Completed Domestically): Peripheral blood karyotype analysis for both partners, whole genome copy number variation sequencing (CNV-seq) to clarify the abnormality type and breakpoint locations. Simultaneously complete AMH, FSH, LH, antral follicle count, semen analysis, and infectious disease screening.
• Hospital Selection and Initial Consultation: Submit previous examination reports to the Georgian reproductive center. The center's genetics team evaluates whether PGT indications are met. Some centers require a video consultation with a genetic counselor.
• Ovarian Stimulation and Egg Retrieval: Conventional antagonist or long protocol stimulation, followed by ICSI fertilization after egg retrieval.
• Embryo Culture and Biopsy: Embryos are cultured to days 5–6 (blastocyst stage). An embryologist creates an opening in the zona pellucida and removes 3–5 trophectoderm cells for testing. The embryo is immediately vitrified after biopsy.
• PGT Testing: Full chromosome aneuploidy screening (PGT-A) or simultaneous analysis of structural rearrangements (PGT-SR) using an NGS platform. The testing period is typically 10–14 days.
• Genetic Counseling and Transfer Decision: Based on the results, the genetic counselor explains the proportion of transferable embryos (euploid/balanced carriers), discusses the transfer sequence, and plans for remaining embryos.
• Endometrial Preparation and Transfer: Prepare the endometrium using a natural cycle or hormone replacement cycle, and transfer a single euploid blastocyst. Blood HCG is tested 10–12 days after transfer.

Which Hospitals in Georgia Can Treat Chromosomal Abnormalities with IVF?

Currently, 4–5 reproductive centers in Georgia routinely offer PGT services, but fewer centers have experience with PGT-SR (structural rearrangement) testing. The following is an objective overview of the industry:

• Zhordania Clinic: Has an independent genetic laboratory, uses NGS platform for PGT-A and PGT-SR, and can screen for balanced translocation, Robertsonian translocation, and inversion. The embryo biopsy team has over 10 years of experience.
• Beta Clinic: Collaborates with European genetic institutions; PGT samples are sent to a German laboratory. Testing covers PGT-A and PGT-SR, but the cycle is slightly longer (results in about 3 weeks).
• In Vitro Clinic: Equipped with an aCGH platform, primarily performs PGT-A, and has accumulated cases for specific structural abnormalities (e.g., reciprocal translocation), but PGT-SR capability needs confirmation regarding the current laboratory capacity.
• Other Centers: Some smaller clinics only offer PGT-A and do not accept complex structural abnormality cases. Before choosing, verify the genetic laboratory's qualifications and the number of PGT-SR cases in the past year.

Criteria for evaluation: The hospital should be able to provide NGS platform test reports, genetic counselor qualification certificates, and clinical pregnancy data for PGT-SR (not success rate promises, but laboratory quality control indicators).

Physician's Perspective · Clinical Considerations for PGT in Chromosomal Abnormality Patients

From a reproductive physician's viewpoint, performing PGT for patients with chromosomal abnormalities requires integrating the following factors:

• Abnormality Type Determines PGT Strategy: Reciprocal translocation and Robertsonian translocation are suitable for PGT-SR; inversion, insertion, microdeletion/duplication choose PGT-SR or PGT-HD based on fragment size; aneuploidy (e.g., 47,XXY) is suitable for PGT-A. The rate of transferable embryos varies significantly by type (reciprocal translocation about 15%–30%, Robertsonian translocation about 25%–40%).
• Age is an Independent Variable: When female age is ≥38 years, even if the chromosomal abnormality itself is manageable, the叠加 risk of aneuploidy further reduces the rate of transferable embryos. Physicians will recommend prioritizing an embryo accumulation strategy.
• Previous Miscarriage History Provides Decision Basis: For carriers with ≥2 early miscarriages, the benefit of PGT is clearer. For sporadic miscarriage where the chromosomal abnormality is a de novo mutation, genetic counseling is needed to assess recurrence risk.
• Laboratory Capability is a Hard Constraint: PGT-SR has higher requirements for biopsy timing, sample transport, and detection platform resolution. Physicians will preferentially recommend centers with a complete closed loop (biopsy + testing + counseling).

Easiest Details to Overlook · Timing Window for Embryo Culture and Biopsy

In PGT cycles for patients with chromosomal abnormalities, three details are often overlooked but directly affect outcomes:

• Biopsy Timing Must Be Strictly on Days 5–6: Day 3 cleavage-stage biopsy was previously used for PGT, but the misdiagnosis rate for mosaicism is high. The international standard has shifted to blastocyst-stage biopsy. If some centers in Georgia still use cleavage-stage biopsy, careful evaluation is needed.
• Embryo Development May Be Slower: The rate of blastocyst formation in embryos from carriers of chromosomal abnormalities may be lower than in the general population, especially in translocation carriers. Physicians need to inform patients in advance about the risk of "no embryos available for testing."
• Survival of Frozen Embryos After Thawing: Blastocysts after biopsy undergo vitrification, with a survival rate generally >95%, but repeated freeze-thaw cycles (e.g., freezing eggs first, then thawing for ICSI) increase risk. It is recommended to complete biopsy and freezing within the same cycle to avoid double freezing.

What to Watch For: Confirm whether the center uses laser-assisted hatching and ultra-rapid vitrification technology, as these directly affect embryo survival after biopsy.

Common Pitfalls · Information Asymmetry in Hospital Selection

Based on practitioner observations, patients with chromosomal abnormalities often encounter the following misconceptions when choosing a hospital in Georgia:

• Only Looking at Success Rate Numbers, Not the Denominator: Some centers publish PGT success rates based on young, non-chromosomal abnormality populations. Applying these directly overestimates one's own probability of having transferable embryos. Patients should ask the hospital to provide cycle numbers and outcomes for the chromosomal abnormality subgroup.
• Neglecting the Genetic Counseling Step: Pre-PGT genetic counseling is not just "signing a consent form"; it involves assessing whether the abnormality type is suitable for PGT and whether there is a better screening strategy (e.g., PGT-SR vs. PGT-A+CMA). Centers lacking genetic counseling may lead to incorrect testing protocol selection.
• Information Delay Due to Sample Outsourcing: Some Georgian centers send biopsy samples to Germany, Spain, or the USA for testing. During this time, sample transport risks (delays, temperature fluctuations) occasionally occur. Before choosing, ask about the testing laboratory location and logistics SOP.
• Unclear Definition of "Transferable Embryo": Some centers define "euploid" as transferable, but for carriers of chromosomal abnormalities, "balanced carrier" embryos (structurally normal but carrying the same translocation as the parents) are also transferable. Confirm whether the report distinguishes between "completely normal" and "balanced carrier."

Differences Between Countries · Comparison of Georgia with Ukraine, Russia, and the USA

When choosing a destination for overseas IVF, patients with chromosomal abnormalities often compare the following four regions:

How to Choose: If the budget is limited and the abnormality type is Robertsonian translocation or inversion (higher transferable embryo rate), Georgia offers a cost-effective advantage. For complex structural abnormalities (e.g., triple translocation, chromosomal fragmentation), priority should be given to genetic laboratories in Russia or the USA, which have more extensive PGT-SR experience. Ukraine's current situation is unstable, requiring additional consideration of travel risks.

Frequently Asked Questions · Common Queries About IVF for Chromosomal Abnormalities

• Q: Can PGT for balanced translocation screen out completely normal embryos?
  A: Yes. PGT-SR can distinguish between three types: "completely normal," "balanced carrier," and "unbalanced." Both completely normal and balanced carrier embryos are transferable. The latter is theoretically no different from a normal person and does not increase the risk of chromosomal abnormalities in offspring.
• Q: How long does it take for a Georgian IVF hospital to produce a PGT report for chromosomal abnormality patients?
  A: If the hospital has its own NGS platform, it usually takes 10–14 days. If samples are sent to a European laboratory, it takes 18–25 days. It is recommended to confirm the reporting cycle before ovarian stimulation to plan the transfer window.
• Q: Can PGT for chromosomal abnormalities still be done with low AMH?
  A: When AMH <1.0 ng/mL, the number of eggs retrieved in a single cycle may be insufficient, leading to few blastocysts and no embryos to test. In such cases, it is recommended to first accumulate embryos over 1–2 cycles before统一 biopsy. The physician will make a comprehensive judgment based on FSH and antral follicle count.
• Q: Does PGT testing harm the embryo?
  A: Blastocyst-stage biopsy removes 3–5 trophectoderm cells and does not affect the inner cell mass. Large-scale data currently show no significant difference in implantation rates between biopsied and non-biopsied blastocysts. However, there is a minor loss (<5%) during the freeze-thaw process after biopsy.
• Q: What materials do patients with chromosomal abnormalities need to prepare for IVF in Georgia?
  A: ID cards and passports (valid for at least 6 months) for both partners, marriage certificate, previous chromosomal karyotype reports, genetic test reports from miscarriage tissue (if available), AMH and hormone panel, and male semen analysis. All reports must have English translations.
• Q: How long does a PGT cycle take? Can some tests be done domestically?
  A: Yes. Chromosomal karyotype analysis, hormone tests, and infectious disease screening can all be completed at a tertiary hospital in your home country, valid for 3–6 months. Ovarian stimulation, egg retrieval, biopsy, and transfer must be done in Georgia. The total stay in Georgia is about 14–18 days (stimulation + retrieval), and another 5–7 days for the transfer phase.

Interpretation of Key Tests · Essential Pre-IVF Checks for Chromosomal Abnormalities

Why These Indicators Are Important: The rate of transferable embryos for patients with chromosomal abnormalities is already low. If ovarian reserve or sperm quality is also compromised, the probability of obtaining a transferable embryo decreases further. Evaluating these indicators in advance helps physicians formulate a more realistic treatment strategy—such as recommending egg/embryo accumulation first, or considering egg/sperm donation as a backup plan.

This content is compiled based on public knowledge and clinical consensus in the assisted reproduction field, intended for patient education reference only and does not constitute medical advice. Specific diagnosis and treatment plans should be based on consultation with a licensed physician.